Treatment of psoriatic arthritis with oral 1,25‐dihydroxyvitamin D3: a pilot study
Open Access
- 1 November 1990
- journal article
- research article
- Published by Wiley in Arthritis & Rheumatism
- Vol. 33 (11) , 1723-1727
- https://doi.org/10.1002/art.1780331117
Abstract
We conducted a 6‐month open‐label trial in which 10 patients with active psoriatic arthritis received 2 m̈g of oral 1,25‐dihydroxyvitamin D3 daily. Statistically significant improvement was noted in the tender joint count and physician global impression. Of these 10 patients, 4 had substantial (≥50%) improvement, and 3 had moderate (≥25%) improvement in the tender joint count. Two patients were unable to receive therapeutic doses because of hypercalciuria. High‐dose vitamin D may be a useful therapeutic agent for psoriatic arthritis.This publication has 13 references indexed in Scilit:
- Which traditional measures should be used in rheumatoid arthritis clinical trials?Arthritis & Rheumatism, 1989
- 1,25‐Dihydroxyvitamin D3 POtentiates the in vitro inhibitory effects of cyclosporin A on T cells from rheumatoid arthritis patientsArthritis & Rheumatism, 1989
- A novel approach for the evaluation and treatment of psoriasis: Oral or topical use of 1,25-dihydroxyvitamin D3 can be a safe and effective therapy for psoriasisJournal of the American Academy of Dermatology, 1988
- Regulation of lymphokine production and human T lymphocyte activation by 1,25-dihydroxyvitamin D3. Specific inhibition at the level of messenger RNA.Journal of Clinical Investigation, 1987
- Auranofin therapy and quality of life in patients with rheumatoid arthritis. Results of a multicenter trialThe American Journal of Medicine, 1986
- Differential effects of 1,25-dihydroxyvitamin D3 on human lymphocytes and monocyte/macrophages: Inhibition of interleukin-2 and augmentation of interleukin-1 productionCellular Immunology, 1986
- Outcome assessment in clinical trials evidence for the sensitivity of a health status measureArthritis & Rheumatism, 1984
- Inhibition of T lymphocyte mitogenesis by 1,25-dihydroxyvitamin D3 (calcitriol).Journal of Clinical Investigation, 1984
- THERAPEUTIC CRITERIA IN RHEUMATOID ARTHRITISJAMA, 1949